Application of menopausal hormone therapy combined with Dingkundan in perimenopausal syndrome
LI Lijun1 CHEN Xuemei2 LUO Suqin1 LIU Wei1 XIONG Jieqi1 XIE Xiaohua1 YANG Huimin1
1. Gynecological Clinic, Jiangxi Maternal and Child Health Care Hospital, Jiangxi Province, Nanchang 330006, China;
2. Department of Obstetrics and Gynecology, Jing′an People′s Hospital, Jiangxi Province, Jing′an 330600, China
Abstract：Objective To investigate the application effect of Estradiol/Estradiol-Dydrogesterone Tablets combined with Dingkundan in perimenopausal syndrome. Methods A total of 30 patients with perimenopausal syndrome who were admitted to Jiangxi Maternal and Child Health Hospital from January to December 2020 were selected as the research objects, and they were divided into the control group and the observation group by random number table method, 15 cases in each group. The control group received Estradiol/Estradiol-Dydrogesterone Tablet treatment, and the observation group received Dingkundan treatment on the basis of the control group. The degree of symptom improvement, coagulation function, quality of life and the incidence of adverse reactions were compared between the two groups. Results There were no significant differences in the scores of modified Kupperman menopausal index (KMI), coagulation function index and the scores of quality of life index between the two groups before treatment(P>0.05).The KMI score of patients in the observation group after treatment was lower than that of the control group, and the difference was statistically significant (P<0.05).After treatment,the levels of prothrombin time(PT)and partial prothrombin time(APTT)of the observation group were shorter than those of the control group, the levels of original (FIB) and D-Ⅱpolymer (D-Ⅱ) of the observation group were lower than those of the control group, and the level of antithrombin Ⅲ (AT-Ⅲ) of the observation group was higher than that of the control group, and the differences were statistically significant (P<0.05). There was no significant difference in thrombin time (TT) after treatment between the two groups (P>0.05). After treatment, the quality of life score of the observation group was higher than that of the control group, and the difference was statistically significant (P<0.05). The incidence of breast tenderness in the observation group was 26.67%, which was lower than that in the control group (86.67%), and the difference was statistically significant (P<0.05). Conclusion Patients with perimenopausal syndrome receiving Estradiol/Estradiol-Dydrogesterone Tablets combined with Dingkundan therapy can better improve symptoms, reduce the adverse effects on coagulation function, and improve the quality of life of patients.
京公网安备 11010502046607号